Total Revenue (PEMGARDA Product)

Not explicitly provided

PEMGARDA revenue of $13.8 million in Q4 2024 reflects the successful commercialization of the product, marking a significant milestone compared to prior periods when revenue was either lower or not generated from product sales. "

Cash and Cash Equivalents

Decrease of approximately 65% YoY from 200,641 thousand USD in Q4 2023 to 69,349 thousand USD in Q4 2024

A marked decline in liquidity is driven by heightened operating expenditures—including costs tied to product commercialization—and reduced proceeds from financial activities, which sharply contrasts with the prior period’s higher cash levels. " " " " "

Total Current Assets

Fell roughly 55% YoY from 224,881 thousand USD in Q4 2023 to 100,681 thousand USD in Q4 2024

A substantial reduction in current assets occurred primarily due to the decreased cash balance combined with lower levels of other short-term assets, reflecting the company's significant operational cash usage compared to the previous period. " " " " "

Total Stockholders’ Equity

Decreased about 62% YoY from 177,468 thousand USD in Q4 2023 to 67,539 thousand USD in Q4 2024

The steep decline in equity is primarily attributable to a very large net loss in Q4 2024, which, in combination with an increasing accumulated deficit and minimal offsetting stock-based compensation or equity issuances, has eroded the balance sheet in stark contrast to the prior period. " " " " "

Net Loss

Not directly compared YoY in the provided data; Q4 2024 reported a net loss of 169,925 thousand USD

The significant net loss of 169,925 thousand USD in Q4 2024 underscores escalating operational and commercialization costs, intensifying the negative financial performance relative to previous quarters and contributing heavily to declines in both equity and cash balances. "